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REPORTING QUALITY OF DOUBLE-BLIND RANDOMIZED CONTROLLED 
TRIALS AND ITS ASSOCIATION WITH THE FUNDING AGENCY
Singh N, Agrawal R, Dimri S, Ubhadiya BS, Narvilkar P, Bhanderi M
Heron Health Private Limited, Chandigarh, India
OBJECTIVE: To assess the reporting quality of double-blind randomized controlled trials 
(RCTs) published in the New England Journal of Medicine (NEJM) using Jadad scale and 
to examine the relationship between funding source and quality of reporting. METHODS:
Medline database was searched for RCTs. Search was limited to RCTs published in the last
ﬁ ve years in the NEJM and performed on humans. Quality of reporting was assessed using 
the Jadad scale (1 to 5). The analysis was limited only to the double-blind RCTs assessing
drug or vaccine based intervention. RESULTS: A total of 207 double-blind trials out of
489 RCTs were assessed for reporting quality. Median (mean) Jadad score was 4 (3.8). The 
proportion of trials with Jadad score 5 was 20.8% whereas 5.8% trials received a Jadad
score of 2. None of the trials received a Jadad score of 1. Method of randomization and 
concealment of allocation was adequate in 35.3% and 47.8% trials, respectively. Method
of blinding was adequate in 51.2% of trials. A total of 89.4% trials reported details of 
follow-up and reasons for withdrawal. The quality of reporting was good (Jadad score
 3) in 94.2% studies. Year-wise analysis showed that 100%, 91%, 91%, 94% and 96% 
studies were of good reporting quality in the year 2004, 2005, 2006, 2007, and 2008,
respectively. A Jadad score of 5 was received by 41% (9 out of 22) government sponsored
trials as compared to only 14% (15 out of 107) trials sponsored by industry. CONCLU-
SION: There is a scope for further improvement in reporting of method for randomization,
concealment of allocation and method of blinding. Inﬂ uence of funding agency on the 
quality of reporting could be analyzed further.
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OBJECTIVES: The purpose of this study was to determine the time delay from the 
diagnosis of primer breast cancer to the appaerance of secondary tumors affecting other
organs in Hungary. METHODS: Data were collected from the nationwide ﬁ nancing 
database of the National Health Insurance Fund Administration (OEP). The subject of 
the observation aimed female patients treated in hospitals with primary breast tumor 
(BNO: C5000-C5090, D0570, D0590) between the period of January 1, 2002 and 
December 31, 2002. We examined the time delay between the diagnosis of primary
breats cancer in 2002 and its secondary malignancies in the following 5 years.
RESULTS: In 2002, a total of 7548 patients were treated in hospitals with malignant
primary breast tumor. Between 2003 and 2007 2870 primary breast tumor patients 
attended in hospitals with tumor disorders affected any other organs. In the following 
ﬁ ve years after the occurrence of primary breast tumors, secondary malignant tumors 
affecting other organs were occurred in 21.32% of the patients. The ﬁ ve most often 
appeared malignant diseases in the examined period were: malignant tumors in the
bones and bone marrow were diagnosed 29.0 months, malignant tumor in the lung
34.4 months, malignant tumor in the lymph gland 20.3 months, malignant tumor of 
the liver 29.7 months and malignant tumor in the brain and dural tumor 32.3 months 
after the occurrence of primary breast tumors. CONCLUSIONS: In the following ﬁ ve 
years other malignant tumors were occurred in one ﬁ fth of the primary breast tumor
patients. For the diagnoses of the ﬁ ve most often secondary tumors 29.1 months, or
2.4 years were needed. In consideration to all occurred secondary tumors in case of 
the whole population this value is on the average 35.2 months or 2.9 years.
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OBJECTIVES: The purpose of this study was to determine the frequency of occurrence 
of secondary tumors affecting other organs in case of patients suffering from tumor
located in any ﬁ elds of the breast. METHODS: Data were collected from the ﬁ nancing 
database of the National Health Insurance Fund Administration (OEP). The subject 
of the observation aimed female patients treated in hospitals with primary breast
tumor (BNO: C5000-C5090, D0570, D0590) between the period of January 1, 2002 
and December 31, 2002. Accordingly we examined the frequency of occurrence of 
secondary tumors evolving after occurrence of the primary tumor in the following 5 
years (2003–2007). RESULTS: In 2002, a total of 10,378 patients (21,418 cases) were 
treated with malignant breast tumor. 2,870 primary breast tumor patients attended in
hospitals with tumor disorders in any organs between 2003 and 2007. The ﬁ rst ﬁ ve
malignant diseases appeared the most often in the examined period were: malignant
tumors in the bones and bone marrow in 298 patients, malignant tumor in the lung
in 212 patients, malignant tumor in the lymph gland in 186 cases, malignant tumor 
of the liver in 182 cases and malignant brain and dural tumor in 151 cases. The fre-
quency of occurrence of these tumors projected on 10,000 primary breast tumors is 
the following: malignant tumors in the bones and bone marrow in 395 patients, 
malignant tumor in the lung in 281 patients, malignant tumor in the lymph gland in 
246 cases, malignant tumor of the liver in 241 cases and malignant brain and dural
tumor in 200 cases. CONCLUSIONS: In the following 5 years of the primary breast
tumor diseases other malignant tumors affecting other organs were evolved in 21.32% 
of the patients. In 26.67% of the patients no secondary tumors were evolved, but the 
primary tumor needed further treatment.
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THE FEASIBILITY AND COST OF EARLY DETECTION OF PROSTATE
CANCER IN GASTROENTEROLOGY UNITS
Shafran-Tikva S1, Lysy J1, Goldin E1, Greenberg D2
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OBJECTIVES: The American Cancer Society suggests that men over the age of 50 
should have their PSA level checked and undergo a rectal examination for early detec-
tion of prostate cancer. However, rectal examinations are infrequently performed by 
family physicians in Israel. Palpitation of the prostate gland can be performed during
routine rectal examination of patients arriving at gastroenterology units for lower 
digestive system examinations and serve as an additional tier in the early detection of 
prostate cancer. We evaluated the cost and feasibility of routine rectal examinations 
for early detection of prostate cancer in a gastroenterology unit, and follow-up by
family physician. METHODS: Our study population included a convenience sample 
of 554 males (age 50–79) arriving at Hadassah Ein-Kerem Medical Center in Israel. 
During the rectal examination, the gastroenterologist estimated the size, structure and
texture of the prostate gland. Patients with suspected pathological results were referred 
to their family physician for further examinations. We assessed the costs of the screen-
ing and follow-up program using the Ministry of Health price list. These costs included 
the costs of family physician and urologist consultations, PSA test, rectal ultrasound,
and biopsy. RESULTS: In 145 of patients (26.1%), the gastroenterologist found a 
pathological mass in the prostate gland and they were referred to their family physi-
cians. Of the 134 patients who went to their family physician, 58 (43.3%) remained 
for observation and monitoring and 76 (56.7%) were referred to urologists for further 
examination. Three patients were diagnosed with prostate cancer. The total cost of 
the screening and follow-up was $25 per patient and the cost per a prostate cancer
detected was approximately $5000. CONCLUSIONS: Our screening model is appli-
cable, efﬁ cient, easy to implement and can be introduced with minimal investment of 
resources. Further studies are needed to examine the long-term cost-effectiveness of 
such a screening program.
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OBJECTIVES: In Brazil, according to the National Cancer Institute (INCA, 2005), 
approximately 50% of all breast cancer (BC) diagnosis point to advanced cases at 
the time of ﬁ rst presentation (stages III and IV), which results in a maximal 5 
year survival rate of 36% for these women (The Susan G. Komen Breast Cancer 
Foundation). It is supposed that this mortality could be reduced through an improve-
ment of public breast health care to encourage early detection of breast lesions for
the population. Hence, the Associação Hospitalar Moinhos de Vento started a part-
nership with Health Secretary of Porto Alegre (capital of Rio Grande do Sul State) 
to perform a study to measure the impact of annual clinical examinations together
with mammography for underserved women over 40 years old. METHODS: A
total of 9,218 women aged between 40 and 69 year old, living in a delimited 
geographic area connected to 18 Health Care Units of Porto Alegre are being 
studied; BC risk factors are also being assessed. For these, yearly clinical examinations 
and screening mammograms are performed. The analysis is related to the ﬁ rst four
years of the project. Its results are compared against INCA epidemiologic data.
RESULTS: Among the searched universe, 50 women have been diagnosed for BC.
Comparing the cancer staging of these women at diagnosis with INCA data for the 
same region, we have: stage 0 (16% VS 6.7%), stage I (38% VS 20.6%), stage II 
(32% VS 45%), stage III (10% VS 20%) and stage IV (4% VS 7.7%), respectively.
CONCLUSIONS: The study showed that the annual screening associated with preven-
tive mammography for women above 40 year old increased their likelihood of an early 
diagnosis of BC, thus yielding them a better survival and cure prognostic. Therefore, 
the national adoption of this protocol could reduce the high mortality associated with 
this neoplasia.
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OBJECTIVES: The purpose of this study is to examine the relationship between
patient outcomes and conditions of the patients undergoing different treatments for
lung cancer and to estimate the population burden, the cost of cancer, and to examine
treatment choice in clinical decision-making. METHODS: Lung Cancer data were 
extracted from the Medstat MarketScan Database based on ICD9 diagnosis codes.
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Kernel Density Estimation was used to examine the lung disease by Age, Length of 
Stay and Total Charges by patient conditions. Text Miner in Enterprise Miner was
used to examine the data according to text strings of treatment procedures. Then we
predict the occurrence of lung cancer according to patient age, gender, days of stay
and total charge with the predictive modeling in Enterprise Miner. RESULTS: There
were 4718 observations related to lung cancer. There are more inpatient events starting 
at age 40, accelerating at age 50 and 55, and decreasing at 65. Patients with lung 
cancer had a higher probability of a stay of ﬁ ve days, which indicates that there was 
a higher probability of higher cost. We deﬁ ned clusters of procedures with a frequency
showing the effectiveness of treatment for patients. The Decision Tree is optimal with
a 22.9% misclassiﬁ cation rate in the testing set compared with other models in Enter-
prise Miner. CONCLUSIONS: Older patients are more likely to have lung cancers 
that would lead to a higher probability of longer stay and higher costs for the treat-
ment procedure. With text analysis on the procedure codes and KDE, it shows that
Levels IV and VI Surgical pathology, gross and microscopic examination are used for 
patients of higher risk with a higher cost compared to other procedures to diagnose
lung cancer.
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OBJECTIVES: Recent changes to ESA prescribing information recommend initiation
at Hb levels  10 g/dL in cancer chemotherapy patients. Real world clinical and eco-
nomic outcomes data associated with this initiation range for the two FDA-approved
ESAs for this population [epoetin alfa (EPO) and darbepoetin alfa (DARB)] are sparse. 
METHODS: Data collected between December 2003 and September 2008 from 61 
U.S. oncology clinics from the Dosing and Outcomes Study of Erythropoietic Stimulat-
ing Therapies (D.O.S.E.) registry were assessed. Patients were included if they were
initiated on ESAs at baseline (BL) Hb  10 g/dL, age   18 years, and received  
2 doses of either EPO or DARB. Outcomes assessed included transfusion utilization, 
cumulative ESA doses, dose ratio (cumulative dose EPO: DARB) and ESA cost (based 
on cumulative ESA dose and December 2008 wholesale acquisition cost: EPO
$13.77/1000 Units, DARB $4.818/mcg). RESULTS: A total of 545 patients (237 EPO, 
308 DARB) were included. BL characteristics were similar between treatment groups
with regard to age, weight, cancer type and Hb. The mean administered dose was
42,610 Units in the EPO group and 259 mcg in the DARB group with a treatment
interval of 11.6 days and 19.4 days, respectively. Mean treatment duration was similar 
between groups (^65 days, P  0.34). The proportion of patients transfused was similar
between groups (^30%, P  0.70). Mean cumulative administered dose was 318,918
Units for EPO and 1,261 mcg for DARB corresponding to a dose ratio of 253:1 (Units 
EPO: mcg DARB). ESA cost was signiﬁ cantly lower in the EPO group compared to
the DARB group (EPO: $4392, DARB: $6075; P  0.001). CONCLUSIONS: In cancer
chemotherapy patients with Hb  10 g/dL prior to ESA initiation, transfusion utiliza-
tion was similar between groups. However, ESA costs were 28% lower in the EPO
group than the DARB group. These ESA-associated outcomes and cost data are 
informative to stakeholders treating cancer chemotherapy patients.
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COMPARISON OF INFECTION-RELATED HOSPITALIZATION RISK AND
ASSOCIATED COSTS AMONG PATIENTS RECEIVING SARGRAMOSTIM, 
FILGRASTIM, AND PEGFILGRASTIM FOR CHEMOTHERAPY-INDUCED
NEUTROPENIA
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OBJECTIVES: Myelosuppressive chemotherapy can lead to neutropenia and increase 
infection risk. Myeloid growth factors are commonly used to treat/prevent neutrope-
nia. Sargramostim is a granulocyte-macrophage colony-stimulating factor (GM-CSF).
Unlike ﬁ lgrastim and pegﬁ lgrastim, which are granulocyte colony-stimulating factors 
(G-CSFs), sargramostim activates a broader range of myeloid lineage-derived cells. 
Therefore, GM-CSF might reduce infection risk more than G-CSFs. This study com-
pared real-world infection-related hospitalization rates and costs in patients using
G/GM-CSF for chemotherapy-induced neutropenia. METHODS: This retrospective
matched-cohort study analyzed nationally-representative health insurance claims in 
the US in 2000–2007. The sample population included patients who received chemo-
therapy and G/GM-CSF. G/GM-CSF treatment episodes began with the ﬁ rst adminis-
tration of G/GM-CSF and ended when a subsequent administration was 28 days 
after a prior administration. Sargramostim patients were matched 1:1 with ﬁ lgrastim 
and pegﬁ lgrastim patients based on gender and birth year. Outcomes included infec-
tion-related hospitalization rates and the associated costs. Hospitalization rates were 
analyzed using univariate and multivariate Poisson methods; covariates included
myelosuppressive agents received, tumor type, anemia, and comorbidities. RESULTS:
A total of 990 sargramostim-ﬁ lgrastim and 982 sargramostim-pegﬁ lgrastim pairs were 
analyzed. Cohorts had similar baseline characteristics, though differences were 
observed in the fraction of patients with a neutropenia diagnosis (sargramostim 65%, 
ﬁ lgrastim 57%, pegﬁ lgrastim 45%) and who received myelosuppressive agents (sar-
gramostim 54%, ﬁ lgrastim 48%, pegﬁ lgrastim 77%). Sargramostim patients experi-
enced infection-related hospitalizations about half as often as ﬁ lgrastim (p  0.04) or
pegﬁ lgrastim (p  0.06) patients. Multivariate analyses adjusted for confounding 
factors and found that sargramostim patients were 56% less likely to have infection-
related hospitalizations compared to ﬁ lgrastim and pegﬁ lgrastim patients (p  0.03 
for both). Infection-related hospitalization costs for sargramostim patients were $728/
patient/month and $226/patient/month less compared to ﬁ lgrastim (p  0.04) and 
pegﬁ lgrastim patients (p  0.01), respectively. CONCLUSIONS: Among patients with
chemotherapy-induced neutropenia, sargramostim use is associated with reduced risk 
of infection-related hospitalization and lower associated costs compared to ﬁ lgrastim
or pegﬁ lgrastim.
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OBJECTIVES: Breast cancer prevention and control in low-and middle-income coun-
tries (LMCs) are critical emerging issues. Most LMCs lack sufﬁ cient resources for
screening, early detection, and treatment of breast cancer. However, little is known 
about what works to reduce the burden of breast cancer in low-resource settings or
how best to maximize public health interventions. The purpose of this study was to
assemble a knowledge base of studies in LMCs on breast cancer prevention, early 
detection, treatment, and palliative care that address issues of equity, access, and costs. 
METHODS: We conducted a systematic literature search via PUBMED and other 
computerized electronic databases. We classiﬁ ed each citation as relevant, peripherally 
relevant, not relevant, or unknown and maximized the criteria by using free-text words
and medical subject headings. All citations identiﬁ ed were independently reviewed by 
three members of the research team. Relevant studies were selected if they met inclu-
sion criteria: published in English or Spanish between January 1, 1990 and April 30,
2008. RESULTS: A total of 1907 citations were identiﬁ ed, of which, 53.2% were
excluded as “not relevant;” 27.1% were considered likely to be “relevant”; 5.5% were 
coded “peripherally relevant”; and 6.0% were “unknown”. All relevant articles (516) 
coming from 60 LMCs met the inclusion criteria and were abstracted. We found 80 
articles on East Asia/Paciﬁ c countries; 82 on Europe/Central Asia countries; 76 on
Latin American/Caribbean countries; 64 on Middle East/North Africa countries; 100
on South Asia countries; 71 on Sub-Saharan Africa countries; and 43 articles with no
region-speciﬁ c focus. We identiﬁ ed three articles on palliation and end-of-life care and 
a small number of articles reported cost data or economic analyses. CONCLUSIONS:
The review contains a wealth of practical information that would be extremely useful
to the myriad of clinicians and public health professionals working to prevent and 
treat breast cancer in LMCs.
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OBJECTIVES: Worldwide, the association of passive smoking with development of 
lung cancer has been ascertained. However, it remains unknown of the magnitude of 
the association in the Chinese population. We thus systematically reviewed the pub-
lished studies worldwide. METHODS: We searched Medline, EMBASE, and three 
other Chinese databases from their inception to June 30, 2008. We included case-
control and cohort studies that investigated the association of passive smoking with 
lung cancer, and that provided data on the magnitude of the association. Two reviewers 
screened the eligibility, assessed the extent of the bias, and extracted data independently.
We obtained the unadjusted and adjusted estimates of studies. We pooled the trial data 
using the random-effect model and explored the heterogeneity by the pre-speciﬁ ed 
variables. RESULTS: We included 20 studies (n  88,379). One was cohort study (n 
72,829) and 19 case-control studies (cumulative cases: 5977, and controls: 9573). 
Passive smoking increase the risk of lung cancer by 25% (OR  1.25, 95%CI  1.03 
to 1.47). Pooling of adjusted estimates of 10 case-control studies (2704 cases and 3495
controls) showed that the risk of lung cancer increased by 95% (1.95, 1.49 to 2.55).
In female life-long non-smokers, the passive smoking increased the risk of lung cancer
by 77% (1.77, 1.22 to 2.58, n  5685), and increased the risk of squamous cell carci-
noma and adenocarcinoma of female non-smokers by 99% (1.99, 1.19 to 3.33) and 
7% (1.05, 0.45 to 2.51). Because of the limited data, no signiﬁ cant dose-response
relationship was found between the risk of lung cancer and the exposure amounts,
durations and the initiating age. CONCLUSIONS: The increased risk of lung cancer 
associated with passive smoking in the Chinese population has been ascertained.
Passive smoking has a strong association with squamous cell carcinoma.
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OBJECTIVES: Worldwide, the association of smoking with development of lung 
cancer has been ascertained. However, it remains unknown of the magnitude of the 
association in the Chinese population. We thus systematically reviewed the published 
